64Cu-LLP2A for Imaging Hematologic Malignancies

StatusTerminated
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Trial terminated Sponsor's reason: Loss of further funding Show 6 more changesShow less
    • Final enrollment: 21 participants (planned 42)
    • Primary completion date changed from estimate of Mar 31, 2027 to Aug 28, 2026
    • Interventions: 64Cu-LLP2A (Drug), PET/CT (Device) to 64Cu-LLP2A (Drug), PET/CT (Device)
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  3. Start date: Feb 26, 2025 to Mar 20, 2025v7
  4. Collaborators expanded, about 4 wordsv6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Apr 30, 2027 to Mar 31, 2027
    • Start date changed from estimate of Mar 31, 2025 to Feb 26, 2025
    • Site details revised
    v4
  2. Start date: Jan 31, 2025 to Mar 31, 2025
    • Primary and study completion dates: Feb 28, 2027 to Apr 30, 2027
    v3
  3. Start date: Nov 30, 2024 to Jan 31, 2025
    • Primary and study completion dates: Dec 31, 2026 to Feb 28, 2027
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Washington University School of Medicine
498 trials monitored
See 39 trials at risk
Leukemia
2,957 trials monitored
See 176 trials at risk
Non-Hodgkin Lymphoma
2,017 trials monitored
See 114 trials at risk
Multiple Myeloma
1,264 trials monitored
See 78 trials at risk
and 2 more diseases
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Trial Details
NCT Number NCT06636175
Lead Sponsor Washington University School of Medicine
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Related terms Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov